Introduction
Prostate cancer is the second most common male cancer-related death world-wide, emphasizing the failure of mainstay therapeutic regimens to treat advanced disease (1) . A pivotal constraint for prostate cancer research is the lack of diverse in vivo models that accurately reflect the clinic. Expanding the range of prostate cancer models that display key clinicopathological characteristics is vital to; (i) delineate the complex molecular mechanisms underpinning prostate cancer, (ii) identify novel prognostic markers and therapeutic targets, and (iii) accurately establish the efficacy of novel therapies that are urgently needed in the clinic.
Class 1A phosphatidylinositol 3-kinases (PI3Ks) are heterodimers consisting of a regulatory subunit encoded by PIK3R1 (p85/p55α/p50α), PIK3R2 (p85 ) or PIK3R3 (p85 ), and a catalytic subunit encoded by PIK3CA (p110 PIK3CB (p110or PIK3CD (p110) (2, 3) .
Upon activation of receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs) or RAS, PI3K is recruited to the membrane. Here, PI3K catalyses the generation of the second messenger phosphatidylinositol (3, 4, 5) trisphosphate (PIP3), which recruits the serine threonine kinases AKT (Protein kinase B, PKB) and Phosphoinositide-dependent kinase-1 (PDK1) to the membrane, as well as a plethora of other PIP3 binding proteins (4) . The first identified, and most well studied, PIP3 effector is AKT (4) . PDK1 phosphorylates AKT at Thr308, leading to phosphorylation of downstream targets including Tuberous Sclerosis Complex 2 (TSC2) that activates mTOR complex-1 (mTORC1) to promote proliferation, survival and migration (2, 3) .
Phosphorylation of AKT at both Ser473 and Thr308 is required for the full activation of AKT, and has been linked to co-activation of the mTORC1 and mTOR complex-2 (mTORC2) pathways (5) . Key substrates of mTORC2 include AKT at Ser473 (5) , and serum/glucocorticoid regulated kinase-1 (SGK1), which phosphorylates and inactivates the metastasis suppressor NPik3ca mutation drives prostate cancer 5 Myc down-regulated gene-1 (NDRG1/DRG1/CAP43)(6). AKT dephosphorylation by PH domain leucine-rich repeat protein phosphatase (PHLPP) at Ser473 and Protein phosphatase 2 (PP2A) at Thr308 deactivate AKT (5) . The fine tuning of AKT phosphorylation levels mediates AKT pathway activity and subsequent cellular events. In addition, the tumor suppressor Phosphatase and tensin homolog (PTEN) serves to negatively regulate the PI3K cascade by catalysing the dephosphorylation of PIP3 to phosphatidylinositol 4,5-bisphosphate (PIP2).
PTEN also mediates lipid phosphatase-independent tumor suppressor activities via its protein phosphatase domain (2) . PI3K pathway hyperactivation is invariably associated with prostate cancer progression in the clinic, thus presenting an attractive therapeutic target. Indeed, loss of PTEN, a negative regulator of the PI3K pathway, is estimated to occur in 40-50% of prostate cancer patients (7, 8) .
However, PI3K pathway hyperactivation can occur via a range of mechanisms (e.g. PIK3CA oncogenic mutation) that can independently influence downstream signaling events. We sought to determine if genetic drivers of the PI3K pathway that are present in prostate cancer, but have not been investigated previously, can also contribute to prostate cancer initiation/progression.
To this end we generated a new, clinically relevant genetically modified mouse model harbouring a heterozygous activating mutation in Pik3ca specifically within prostate epithelial cells, and compared prostate histopathology with the well-characterised Pten-deleted mouse model of prostate cancer (9) . Overall, our findings emphasize the prognostic value of PI3K genetic drivers to better inform personalised therapy design.
Results

PIK3CA mutation/amplification correlates with advanced prostate cancer progression.
PIK3CA oncogenic mutation and amplification, which may increase p110 PI3K catalytic Pik3ca mutation drives prostate cancer 6 activity, are frequently detected in human cancers (10) (11) (12) (13) . To better understand the frequency of PIK3CA alterations in prostate cancer, we analysed nine prostate cancer genomic datasets for PIK3CA mutations and gene amplification (14) . Our analysis shows that PIK3CA mutations occur in up to 4% of prostate cancer patients, while PIK3CA copy number gain/amplification occurs in as many as 62% of cases (Fig.1A, Supplementary Table 1 ). PIK3CA mutations were predominantly nucleotide missense substitutions (87.5%, Supplementary Fig.1A ) within the helical (44.1%) and kinase (20.6%) domains, and previously reported hotspot mutations in exon 9 (E542K, E545K) and 20 (H1047R)(10-12,15) were most frequent (Fig.1B) . Notably, the majority of PIK3CA mutations observed (83%, 19/23) have been previously detected in prostate or non-prostate malignancies (12, 13, 15, 16) , and are reported to increase p110 activity (12, (15) (16) (17) (18) (Fig.1B) .
To determine if PIK3CA mutation/amplification correlates with prostate cancer progression, we analysed the TCGA provisional prostate cancer dataset (Supplementary Table 2 ). Our analysis revealed that PIK3CA mutation and copy number gain/amplification frequency significantly correlates with poor prostate cancer survival, regional lymph node metastasis, and a higher pT category and Gleason grade (Fig.1C, Supplementary Table 3 ), resembling PTEN loss ( Supplementary Fig.1B, Supplementary Table 4 ).
Co-expression analysis within the nine prostate cancer datasets analysed revealed that 39.4% (13/33 patients) of PIK3CA mutation carriers also harboured PTEN mutation or copy number loss, indicating that PIK3CA mutant prostate cancer patients have a high frequency of coexistent PTEN deleterious genetic alterations, consistent with ovarian, breast, endometrial, and colorectal cancer studies (11, 19, 20 Fig.2A-B Fig.2A -B, and ventral/anterior lobes: Supplementary Fig.2C -E, Supplementary Table 5 ). Invasion was confirmed by the absence of smooth muscle actin (SMA) staining by immunohistochemistry (IHC) (Supplementary Fig.2F ). Pik3ca +/HR prostate carcinomas were predominantly dysplastic/mucinous and reactive stroma and immune infiltrate were evident ( Fig.2A ; 300-400 d, Supplementary Fig.2C ). Taken together, these data Pik3ca mutation drives prostate cancer demonstrate that heterozygous Pik3ca H1047R oncogenic mutation is sufficient to cause invasive prostate cancer in mice, and to our knowledge is the first example of a mono-allelic mutation driving invasive prostate cancer growth in vivo.
To determine if the genetic driver of the PI3K cascade influences prostate tumorigenesis and/or malignant progression, we compared our novel Pik3ca +/HR prostate cancer model with the wellcharacterised Pten-deleted mouse model of prostate cancer (9) . To this end, we generated agematched cohorts of PBiCre +/-;Pten fl/fl mice (denoted Pten fl/fl ) deficient for both copies of Pten within prostate epithelial cells and compared the phenotype on the same genetic background.
In contrast to Pik3ca +/HR mice, we observed early onset of hyperplastic lesions at 56 d and rapid tumor progression from prostate intraepithelial neoplasia (PIN) to locally invasive carcinoma in Pten fl/fl mice by 200 d ( Fig.2A-B, Supplementary Fig.2C -E, Supplementary Table 5) .
Furthermore, Pten fl/fl prostate tumor burden was significantly greater and more heterogenous than the Pik3ca +/HR model ( Fig.2A/C) , as carcinosarcomas were also present by 300 d in 29% of the cohort (2/7). However, metastasis to the liver, lung, lymph nodes or bone was not detected in either model. Pten fl/fl mice were also prone to seminal vesicle neoplasia, urethra neoplasia and adrenal pheochromocytoma that were rare, or absent, in Pik3ca +/HR mice (Supplementary Table 5 (Fig.3A-B) . Supplementary Fig.3C ). Taken together these data show that while a single Pik3ca H1047R activating mutation predisposes to murine prostate cancer, like bi-allelic loss of Pten, these two genetic drivers of the PI3K cascade do not completely phenocopy. Overall, these findings suggest that Pik3ca oncogenic mutation and Pten loss may drive prostate tumor phenotypes via distinct molecular mechanisms, which could present novel therapeutic targets. prostate carcinoma compared to Wt controls (Fig.3C-D) , indicating that both PI3K genetic drivers stimulate mTORC1 signaling to promote tumor growth. In support, the proportion of cells displaying phosphorylation of well-known downstream mTORC1 targets, namely the ribosomal protein S6 (RPS6) at Ser235/236 that regulates cell size and proliferation and 4e-binding protein 1 (4E-BP1) at Thr37/46 that mediates translational machinery, were also significantly elevated in both models ( Thus, mTORC2 signaling presents a direct mechanism whereby Pten homozygous deletion can promote tumor onset/progression relative to Pik3ca H1047R oncogenic mutation in this setting. To directly test p110 and p110 isoform dependency in Pik3ca mutant and Pten deleted prostate cancers, we administered isoform specific inhibitors (A66, a p110-specific inhibitor or TGX-221, a p110-specific inhibitor) or a pan-PI3K inhibitor (BKM120) to cohorts of . These data suggest that p110mediated signaling events could facilitate Ptendeleted prostate cancer but not Pik3ca H1047R mutated prostate cancer, and support previous work showing that combined p110and p110 blockade improves therapeutic outcome in PTEN-deficient prostate cancers compared to PI3K isoform specific monotherapy (22, 26, 28) .
Pik3ca mutation and
Indeed, PI3K pathway inhibitors on their own have been shown to have limited efficacy in the clinic due to multiple feedback loops, PI3K-independent pathways and/or additional oncogenic mutations, and can cause side effects (e.g. hyperglycemia) (22, 26, 28, 29 Fig.5C ). Local invasion was confirmed by the absence of SMA staining ( Supplementary Fig.5C ). Tumor burden was also significantly greater in compound mutants than age-matched single mutants ( Supplementary Fig.5D ). Visceral metastases were not detected by 100 d of age, and the development of non-prostate malignancies reflecting leaky Previous work has shown that amplification/overexpression of Pik3ca and Pik3cb increases oncogenicity (22, 30, 31) , and amplification frequently correlates with poor patient outcome in multiple malignancies (22 (Fig.6A) , histopathological analysis revealed that prostate tumors were still present in Pik3ca +/HR mice, indicating the development of acquired CRPC (Fig.6B, Supplementary Fig.6A ). These findings are in keeping with partial androgen sensitivity and the latent acquisition of CRPC, mirroring homozygous deletion of Pten (Fig.6A and B, Supplementary Fig.6A ), as previously reported(33,34). IHC to detect AR confirmed the reduction of androgens post-castration, as cytoplasmic AR was detected in Pik3ca +/HR and Pten fl/fl prostate epithelial cells following castration, whereas uncastrated controls displayed active nuclear AR (Supplementary Fig.6B ).
To determine if Pik3ca heterozygous oncogenic mutation sensitises pre-neoplastic prostate epithelium to CRPC transition, we examined the short-term and long-term response of Fig.6C-D ). These data demonstrate that Pik3ca-mutated prostate epithelium possesses an inherent ability to acquire CRPC, similarly to Pten loss(9). (Fig.7F) . Nevertheless, the precise role of NDRG1 inactivation (Fig.7G, Supplementary Fig.3B , Pik3ca mutation drives prostate cancer Supplementary Table 7) . RPPA results for p-AKT Thr308 and p-AKT Ser473 were confirmed by Western blotting (Supplementary Fig.7E ).
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RPPA profiles for uncastrated and castrated compound mutants were strikingly similar. Indeed, only 4 targets were significantly altered; p-SHP-2 (Tyr542) and p-SRC family (Tyr416) signals were increased and YAP and CK2 were decreased (Fig.7G, Supplementary Table 7 ). This result contrasts single mutants that acquired CRPC and is consistent with the general lack of effect of castration on the prostate tumors in the double mutant mice (Fig.6C-F) . However, it should be noted that the RPPA was not sensitive enough to detect elevated p-NDRG1 (Thr346)
in Pik3ca +/HR ;Pten fl/fl mutants post-castration that was observed by IHC ( Fig.7E-F) , presumably owing to tumor heterogeneity and/or stromal content, which may also be a contributing factor in the lack of significant difference in other proteins as well. Nevertheless, distinct differences between the Pik3ca +/HR and Pten fl/fl models were detected post-castration ( prostate tumors are p110/ co-dependent, and exhibit accelerated tumor formation and progression owing to AKT-hyperactivation, elevated mTORC2 and RAC1-p110 signaling.
The failure to induce robust AKT signaling in Pik3ca +/HR epithelium is probably attributable to the maintenance of PTEN tumor suppressive function that reduces PIP3 levels, AKT membrane recruitment, and subsequent activation of AKT, as previously reported (35) . In corroboration, Pten loss has been shown to positively correlate with disease progression in mice, as Pten loss of heterozygosity is required for prostate cancer growth in Pten heterozygous prostate epithelium (9) . We speculate that PTEN function is also likely to be conserved in transgenic mice expressing myristoylated/activated AKT or p110 in prostate epithelial cells, as only low-grade prostate epithelial neoplasia develops that does not progress to carcinoma with ageing (36, 37) . Taken together, these observations suggest that additional mTORC2/RAC1/p110-independent cooperative events are likely to facilitate malignant progression to an invasive state in Pik3ca +/HR mutants that express PTEN. Indeed, PIK3CA
mutations have been shown to potentiate a PDK1-SGK3, AKT-independent signaling axis in various human cancer cell lines that express PTEN (35) , and PDK1-SGK1 AKT-independent signaling has been shown to cause resistance to p110 inhibition by directly phosphorylating TSC2 to activate the mTORC1 pathway(38). (35) . PTEN is also reported to play a broader AKTindependent tumor suppressive role via protein-and lipid-phosphatase activities to mediate p53, cell cycle arrest and integrin, insulin and focal adhesion kinase signaling, reviewed in(40).
Thus, developing our combined understanding of AKT regulation, p110 PI3K isoform signaling, and PTEN mode of action during prostate cancer is vital to determine optimal therapeutic approaches that inhibit the PI3K signaling network and subsequently prostate cancer growth and progression.
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Although p110 and p110 isoforms have been shown to form mutually exclusive signaling complexes with RAS and RHO family (RAC1/CDC42) small GTPase protein superfamily members respectively (22) , the molecular mechanisms underpinning their different modes of action are poorly understood. This study provides additional data that underlines a distinct role for the RAC1-p110 signaling axis in Pten-deleted prostate cancer, and raises the possibility that RAC inhibition may show therapeutic efficacy against PTEN-deleted prostate cancer in the clinic, as recently demonstrated for a Pten-null, p110-dependent mouse model of myeloid neoplasia(41). By taking this approach, PI3K-independent functions of PTEN and AKT may be advantageously co-targeted, as RAC1 activation is mediated by PI3K-dependent (e.g.
PREX-1/TIAM/mTORC2) and PI3K-independent (e.g. SRC/p130CAS) signaling(25,42).
We have generated a new clinically relevant transgenic mouse model of advanced prostate cancer driven by concomitant Pik3ca heterozygous oncogenic mutation and Pten homozygous deletion. We show that these two oncogenic drivers cooperate to promote rapid progression to invasive prostate cancer, characterised by the synergistic elevation of mTORC1/2 signaling, AKT super-activation and increased Pik3ca/b mRNA transcript expression. These data provide direct evidence that Pik3ca mutation and Pten deletion coordinate independent oncogenic signaling events during prostate cancer, in corroboration with the distinct RPPA profiles observed. Furthermore, our findings emphasize that the co-existence of mutated PIK3CA and PTEN loss may prove to be an important prognostic indicator for rapid prostate cancer progression and de novo resistance to androgen deprivation therapy in the clinic.
Currently, the cause and consequence of upregulated Pik3ca/b transcription is poorly understood. Theoretically, increased Pik3ca/b gene expression could promote prostate cancer progression in Pik3ca +/HR ;Pten fl/fl mice by increasing p110 protein levels, and thus total Pik3ca mutation drives prostate cancer PI3K activity, as PIK3CA amplification is thought to do in ovarian cancer cells (43) . FOXO3A, NF-kB, YB1 and p53 have been shown to promote PIK3CA transcription (reviewed in(44)), however PIK3CB transcriptional regulators remain to be identified. Further investigation is needed to determine the underlying mechanism by which increased p110 catalytic activity and loss of Pten phosphatase activity cooperate to upregulate Pik3ca and Pik3cb transcription, and to establish the functional significance of this observation.
Despite numerous phenotypic differences, we report that both Pten-null and Pik3ca +/HR -driven prostate cancers are partially sensitive to androgen withdrawal and acquire CRPC in association with augmented PI3K signaling. These data signify that both p110 and p110 It is becoming clear that approaches inhibiting multiple targets within the PI3K network, either simultaneously or sequentially, are necessary to enhance therapeutic efficacy. Thus, further characterization of p110-mediated signaling, PI3K-independent PTEN tumor suppressive functions, AKT-independent signaling and AKT regulation is required to improve our understanding of how to target the PI3K network and identify mechanisms of therapeutic resistance to improve our management of prostate cancer in the clinic. Future work addressing how to personalise treatment for tumors driven by diverse PI3K genetic drivers is paramount, and is likely to entail the co-inhibition of PI3K-dependent and PI3K/AKT-independent signaling pathways.
Materials and Methods
Experimental animals: PBiCre transgenic mice that express Cre recombinase under the control of the Probasin promoter and Pten fl/fl mice have been described previously (21, 48) . Pik3ca H1047R mutant mice were generated in-house (11) . All mice were maintained on a pure FVB/NJ background. Mice were genotyped from DNA isolated from toe biopsies, as described previously (11, 49) . Age-matched males were randomly assigned to uncastrated/castrated cohorts. Castration experiments involved the surgical removal of the testis and epididymis.
Animal experiments followed the National Health and Medical Research Council (NHMRC) Immunohistochemistry: Staining was carried out as described previously (49) replicate pairs were adequately correlated (correlation coefficient >0.9). Data were Log2-normalised, median centered and re-scaled between 0-1 using the formula;
represents a vector of antibody responses for a given sample. The RPPA heatmap was generated in R using pheatmap.
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Analysis of genomic datasets: Analysis of PIK3CA gene mutation/amplification was performed on prostate cancer patient datasets with sequencing and copy number alteration (CNA) data using the cBioPortal platform (14) . The TCGA provisional dataset was downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/); PIK3CA segment mean Log R-Ratio ≥0.1γ5.
To minimise CNA noise, probe number was filtered to ≤10. Silent mutations were excluded.
Statistical analysis: Prostate weight and IHC scoring were analysed using a one-way ANOVA with Tukey's correction or an unpaired t-test (95% confidence interval) as indicated using GraphPad Prism_7.03 software. Kaplan-Meier plots were generated, and age-adjusted COX proportional hazard regression ratio calculated using R software. For RPPA, an unpaired twotailed t-test with Welch's correction was calculated using R software. P<0.05 was considered statistically significant. 
